Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

 
• By Jessica Merrill
text 10 percentages discount 3d red white banner, letters and block, business concept
Truxima will launch at a 10% lower WAC than Rituxan • Source: Shutterstock

More from New Products

More from Scrip